Biodexa Ltd, a clinical stage biopharmaceutical company, has successfully completed the enrollment and treatment phase of the Phase 1 study for MTX110. This study focused on treating children with newly diagnosed Diffuse Midline Gliomas (DMGs), a type of primary brain tumor that primarily affects children and has a poor prognosis.
The study took place at Columbia University Irving Medical Centre and enrolled nine pediatric patients between the ages of 4 and 17. All patients underwent radiation therapy followed by surgery, which involved implanting an intratumoral catheter and subcutaneous pump. Eight out of nine patients received two infusions of MTX110 via convection-enhanced delivery (CED) without experiencing any dose limiting toxicities.
MTX110 is a water-soluble form of panobinostat free base that allows for targeted delivery directly to the tumor site. It offers hope as a potential treatment option for DMGs, which currently lack effective therapies. The full results of this Phase 1 study are anticipated to be released in the first quarter of 2024.